Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer

被引：0
|
作者：
Toffart, A. -C. [1 ,2 ]
Sakhri, L. [1 ,2 ]
Moro-Sibilot, D. [1 ,2 ]
机构：
[1] Ctr Hosp Univ A Michallon, UM Oncol Thorac, F-38043 Grenoble 9, France
[2] Univ Grenoble 1, Inst A Bonniot, INSERM, U823, Grenoble, France
来源：
REVUE DE PNEUMOLOGIE CLINIQUE | 2013年 / 69卷 / 02期
关键词：
EML4-ALK; Lung cancer; Crizotinib; Targeted therapy; Never smoker; Adenocarcinoma; EML4-ALK FUSION GENE; KINASE INHIBITOR; RESISTANCE; REARRANGEMENT; MUTATIONS; EFFICACY; MET; NPM;
D O I：
10.1016/j.pneumo.2012.11.010
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Crizotinib is a small orally-administered ALK inhibitor for patients with non-small cell lung cancer with EML4-ALK rearrangement (echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase). This fusion gene is detected with a break apart fluorescence in situ hybridization (FISH) assay. Phase I to III trials have shown an interesting disease control rate and acceptable tolerability. Crizotinib is available in France under temporary use authorization. New potentially effective therapeutics in ALK-positive NSCLC are being developed. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：111 / 116
页数：6
相关论文
共 50 条
  • [31] UPDATED RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Kim, D.
    Ahn, M.
    Yang, P.
    Liu, X.
    De Pas, T.
    Crino, L.
    Lanzalone, S.
    Polli, A.
    Shaw, A.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 402 - 402
  • [32] Comparison of cardiovascular effects of crizotinib and chemotherapy in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Wilner, K.
    Usari, T.
    Polli, A.
    Kim, E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S133 - S133
  • [33] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M. J.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, R.
    Kim, D. -W.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Gupta, N.
    Haney, J.
    Kerstein, D.
    Popat, S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21): : 2027 - 2039
  • [34] Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer
    Wilner, Keith D.
    Usari, Tiziana
    Polli, Anna
    Kim, Elizabeth E.
    [J]. FUTURE ONCOLOGY, 2019, 15 (10) : 1097 - 1103
  • [35] Future options for ALK-positive non-small cell lung cancer
    Iacono, Daniela
    Chiari, Rita
    Metro, Giulio
    Bennati, Chiara
    Bellezza, Guido
    Cenci, Matteo
    Ricciuti, Biagio
    Sidoni, Angelo
    Baglivo, Sara
    Minotti, Vincenzo
    Crino, Lucio
    [J]. LUNG CANCER, 2015, 87 (03) : 211 - 219
  • [36] Brigatinib as a treatment of ALK-positive non-small cell lung cancer
    De Carlo, Elisa
    Stanzione, Brigida
    Del Conte, Alessandro
    Revelant, Alberto
    Bearz, Alessandra
    [J]. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (05): : 299 - 305
  • [37] Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients
    Bendaly, Edmond
    Dalal, Anand A.
    Culver, Kenneth
    Galebach, Philip
    Bocharova, Iryna
    Foster, Rebekah
    Sasane, Medha
    Macalalad, Alexander R.
    Guerin, Annie
    [J]. ADVANCES IN THERAPY, 2017, 34 (07) : 1673 - 1685
  • [38] Perioperative crizotinib in a patient with stage IIIB ALK-positive non-small cell lung cancer: a case report
    Tian, Yu
    Huang, Jia
    Li, Chongwu
    Jiang, Long
    Lin, Hao
    Lu, Peiji
    Luo, Qingquan
    Yang, Guocai
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (12)
  • [39] Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib
    Davis, K. L.
    Kaye, J. A.
    Masters, E. T.
    Iyer, S.
    [J]. CURRENT ONCOLOGY, 2018, 25 (01) : E40 - E49
  • [40] Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib
    Olmez, O. F.
    Bilici, A.
    Gursoy, P.
    Cubukcu, E.
    Sakin, A.
    Korkmaz, T.
    Cil, I.
    Cakar, B.
    Menekse, S.
    Demir, T.
    Acikgoz, O.
    Hamdard, J.
    [J]. PULMONOLOGY, 2023, 29 (06): : 478 - 485
12345